---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-158951"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:51:11.072261+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Three Sensei directors to resign, new CEO & CFO conditional on stockholder approval

## Summary
- Christopher Gerry, Thomas Ricks, Kristian Humer resigning conditionally effective after June 10, 2026 annual meeting, contingent on stockholder approval of Conversion and Charter Amendment Proposals.
- Conditional appointments of Stephen Hahn, Saira Ramasastry, Karen Vousden as new directors effective at same time.
- If proposals approved, Anand Parikh (current COO) will become CEO; Brian Stephenson will become CFO. Gerry remains General Counsel, Craver remains SVP Finance.
- Board adopted Severance and Change in Control Plan covering Parikh, Gerry, Craver with cash severance up to 18 months base salary and COBRA.
- Conversion Proposal involves issuance of >20% of common upon Series B preferred conversion, resulting in change of control.

## SEC filing metadata
- accession: 0001193125-26-158951
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.9
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526158951/0001193125-26-158951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526158951/d85136d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-158951
- JSON: https://secwatch.observer/filing/0001193125-26-158951.json
- Plain text: https://secwatch.observer/filing/0001193125-26-158951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.